Aurora Cannabis Inc (ACB) FinancialsACBFinancialAurora Cannabis Inc

Aurora Cannabis Inc (ACB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cannabis, accounting for 87.2% of total sales, equivalent to CAD 78.81M. Another important revenue stream is Plant propagation. Understanding this composition is critical for investors evaluating how ACB navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Aurora Cannabis Inc maintains a gross margin of -5.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -67.86%, while the net margin is -5.97%. These profitability ratios, combined with a Return on Equity (ROE) of -7.09%, provide a clear picture of how effectively ACB converts its operational activities into shareholder value.

In the context of the broader market, ACB competes directly with industry leaders such as MGPI and VFF. With a market capitalization of $232.98M, it holds a significant position in the sector. When comparing efficiency, ACB's gross margin of -5.95% stands against MGPI's 37.37% and VFF's 46.85%. Such benchmarking helps identify whether Aurora Cannabis Inc is trading at a premium or discount relative to its financial performance.

Aurora's financial performance shows volatility, with net income fluctuating significantly. For instance, in Q2 2026, the company reported a net income loss of CAD 51.47 million, while in Q3 2026, it achieved a slight profit of CAD 1.82 million. The gross margin has also varied widely, from -8.86% in Q2 2026 to 47.68% in Q4 2026, indicating inconsistent profitability.